Sienna Biopharmaceuticals (SNNA) Short Interest Ratio & Short Volume

Short interest is the volume of Sienna Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of December 13th, traders have sold 483,800 shares of SNNA short. 2.17% of Sienna Biopharmaceuticals' shares are currently sold short. Learn More on Sienna Biopharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.17% of Sienna Biopharmaceuticals' floating shares are currently sold short.

Sienna Biopharmaceuticals saw a increase in short interest during the month of December. As of December 13th, there was short interest totaling 483,800 shares, an increase of 95.6% from the previous total of 247,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Sienna Biopharmaceuticals currently has issued a total of 30,908,000 shares. Some of Sienna Biopharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Sienna Biopharmaceuticals currently has a public float of 22,270,000 shares.

2.17% of Sienna Biopharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Sienna Biopharmaceuticals: Kintara Therapeutics, Inc. (1.69%), Biophytis S.A. (0.73%), Tharimmune, Inc. (0.65%), Virpax Pharmaceuticals, Inc. (3.42%), Cingulate Inc. (1.21%), ZyVersa Therapeutics, Inc. (8.09%), Processa Pharmaceuticals, Inc. (1.56%), Evoke Pharma, Inc. (0.78%), Genprex, Inc. (3.78%), Lipella Pharmaceuticals Inc. (1.24%),

As of the most recent reporting period, the following stocks had the largest short interest positions: The Medicines Company ($2.12 billion), Genesee & Wyoming Inc ($433.11 million), Clovis Oncology ($306.74 million), Neogen Co. ($179.22 million), Jagged Peak Energy Inc ($168.19 million), Perdoceo Education Co. ($96.30 million), Arbor Realty Trust, Inc. ($89.67 million), Carbonite Inc ($65.84 million), Overstock.com, Inc. ($58.63 million), and Abeona Therapeutics Inc ($14.62 million). View all of the most shorted stocks.

Short selling SNNA is an investing strategy that aims to generate trading profit from Sienna Biopharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Sienna Biopharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SNNA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SNNA, twice per month. The most recent reporting period available is December, 13 2019.